WallStreetZenWallStreetZen

NYSE: EBS
Emergent Biosolutions Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EBS

Based on 1 analyst offering 12 month price targets for Emergent Biosolutions Inc

Min Forecast
$10.00+69.2%
Avg Forecast
$10.00+69.2%
Max Forecast
$10.00+69.2%

Should I buy or sell EBS stock?

Based on 2 analysts offering ratings for Emergent Biosolutions Inc.

Sell
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
1 analysts 50%
Although EBS's forecast from analysts indicates a "Sell", our proven Zen Rating quant model rates EBS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their EBS stock forecasts and price targets.

EBS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-21
lockedlocked$00.00+00.00%2026-08-10

1 of 1

Forecast return on equity

Is EBS forecast to generate an efficient return?

Company
N/A
Industry
62.34%
Market
167.72%

Forecast return on assets

Is EBS forecast to generate an efficient return on assets?

Company
N/A
Industry
23.61%

EBS earnings per share forecast

What is EBS's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.36
Avg 2 year Forecast
$1.06
Avg 3 year Forecast
$1.59

EBS revenue forecast

What is EBS's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$663.7M-13.83%
Avg 2 year Forecast
$710.5M-7.75%
Avg 3 year Forecast
$634.3M-17.65%
EBS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EBS revenue growth forecast

How is EBS forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-4.83%
Industry
10.53%
Market
13.43%
EBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EBS vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
EBS$5.91$10.00+69.20%Sell
ACB$4.01N/AN/A
CRDL$1.94$9.50+389.69%Strong Buy
ORGO$1.74$5.00+187.36%Buy
TKNO$7.12$7.50+5.34%Strong Buy
View Top Pharmaceutical Stocks

Emergent Biosolutions Stock Forecast FAQ

Is Emergent Biosolutions Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: EBS) stock is to Sell EBS stock.

Out of 2 analysts, 0 (0%) are recommending EBS as a Strong Buy, 1 (50%) are recommending EBS as a Buy, 0 (0%) are recommending EBS as a Hold, 0 (0%) are recommending EBS as a Sell, and 1 (50%) are recommending EBS as a Strong Sell.

If you're new to stock investing, here's how to buy Emergent Biosolutions stock.

What is EBS's earnings growth forecast for 2026-2028?

(NYSE: EBS) Emergent Biosolutions's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 18.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.03%.

Emergent Biosolutions's earnings in 2026 is -$176,800,000.On average, 4 Wall Street analysts forecast EBS's earnings for 2026 to be $18,642,985, with the lowest EBS earnings forecast at $18,089,233, and the highest EBS earnings forecast at $19,381,321. On average, 3 Wall Street analysts forecast EBS's earnings for 2027 to be $54,375,373, with the lowest EBS earnings forecast at $52,760,263, and the highest EBS earnings forecast at $56,528,853.

In 2028, EBS is forecast to generate $81,304,129 in earnings, with the lowest earnings forecast at $78,889,155 and the highest earnings forecast at $84,524,094.

What is EBS's revenue growth forecast for 2026-2028?

(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of -4.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.43%.

Emergent Biosolutions's revenue in 2026 is $770,200,000.On average, 4 Wall Street analysts forecast EBS's revenue for 2026 to be $34,030,113,103, with the lowest EBS revenue forecast at $32,409,875,686, and the highest EBS revenue forecast at $35,876,978,666. On average, 3 Wall Street analysts forecast EBS's revenue for 2027 to be $36,431,756,161, with the lowest EBS revenue forecast at $29,997,977,960, and the highest EBS revenue forecast at $43,607,972,268.

In 2028, EBS is forecast to generate $32,521,651,558 in revenue, with the lowest revenue forecast at $31,555,661,908 and the highest revenue forecast at $33,809,637,758.

What is EBS's forecast return on assets (ROA) for 2026-2029?

(NYSE: EBS) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 23.61%.

What is EBS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EBS price target, the average EBS price target is $10.00, with the highest EBS stock price forecast at $10.00 and the lowest EBS stock price forecast at $10.00.

The Wall Street analyst predicted that Emergent Biosolutions's share price could reach $10.00 by Aug 21, 2027. The average Emergent Biosolutions stock price prediction forecasts a potential upside of 69.2% from the current EBS share price of $5.91.

What is EBS's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: EBS) Emergent Biosolutions's current Earnings Per Share (EPS) is -$3.41. On average, analysts forecast that EBS's EPS will be $0.36 for 2026, with the lowest EPS forecast at $0.35, and the highest EPS forecast at $0.38. On average, analysts forecast that EBS's EPS will be $1.06 for 2027, with the lowest EPS forecast at $1.03, and the highest EPS forecast at $1.10. In 2028, EBS's EPS is forecast to hit $1.59 (min: $1.54, max: $1.65).

What is EBS's forecast return on equity (ROE) for 2026-2029?

(NYSE: EBS) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.